On September 25, 2019 Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, reported it has enrolled 158 patients in its Phase 2 trial of AG013 for the treatment of severe oral mucositis (Press release, Oragenics, SEP 25, 2019, View Source [SID1234539778]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, the Data and Safety Monitoring Board (DSMB) for the trial, recently met and reviewed safety data to date and has determined that the trial may continue with no adjustments or further review. The company is currently enrolling approximately 200 patients in 59 study sites in the United States and Europe.

"Having reached more than three quarters enrollment is an important milestone for this trial, and we remain on track to complete enrollment by the end of the fourth quarter of 2019. In the meantime, we are grateful to our DSMB for their continued support in reviewing our incremental safety data and clearing the trial to continue uninterrupted. Finally, we look forward to providing additional updates on the progress and data from the trial as it becomes available," stated Alan Joslyn, CEO of Oragenics, Inc.

AG013, which has been granted Fast Track designation with the U.S. Food and Drug Administration and orphan drug status in Europe, is an ActoBiotics therapeutic candidate formulated to deliver the therapeutic molecule Trefoil Factor 1 to the mucosal tissues in the oral cavity in a convenient oral rinsing solution. Trefoil Factors are a class of peptides involved in the protection of gastrointestinal tissues against mucosal damage and play an important role in subsequent repair. The compound was designed by the company’s strategic partner, ActoBio Therapeutics, Inc., a wholly-owned subsidiary of Intrexon Corporation (NYSE: XON).

On September 25, 2019 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, reported that the Company’s management will present a Company overview and update, as well as host investor meetings, at the 2019 Cantor Global Healthcare conference (Press release, Supernus, SEP 25, 2019, View Source [SID1234539776]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Thursday, October 3, 2019
Time: 5:20 p.m. ET
Place: InterContinental New York Barclay, New York City

Investors interested in arranging a meeting with the Company’s management during this conference should contact the conference coordinator.

A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investor Relations section on the Company’s website at www.supernus.com. An archived replay of the webcast will be available for 60 days on the Company’s website after the conference.

On September 25, 2019 Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine metastatic breast cancer arena, reported that it will present a poster at the 2019 Annual Meeting of the North American Menopause Society (NAMS) on oncologists’ perception of sexual intimacy concerns by patients with metastatic breast cancer (Press release, Sermonix Pharmaceuticals, SEP 25, 2019, View Source [SID1234539775]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation of the poster "Oncologists’ Perception of Sexual Intimacy Issues in Metastatic Breast Cancer: An Opportunity to Address Patientsʼ Concerns and Improve Quality of Life" will be held Sept. 26 from 6 p.m. to 7 p.m. at the Hyatt Regency in Chicago.

"This survey’s results confirm the need for oncology practitioner medical education programs that increase awareness, knowledge, and communication tools, providing patients undergoing treatment for metastatic breast cancer with options and resources that may improve their ability to be intimate with partners as they traverse their challenging journey," said presenting author Dr. Lisa Larkin, M.D., founder and chief executive officer of Ms. Medicine. "I look forward to detailing the survey’s findings at the NAMS Annual Meeting."

The study follows a University of Michigan patient-based survey that found sexual concerns were very common for women undergoing treatment for metastatic breast cancer and that these concerns often were overlooked by their oncologists.1

"Those of us with metastatic breast cancer know our lives will be shortened because of this disease, but our sex lives shouldn’t suffer an even earlier death," said Dr. Kelly Shanahan, a patient advocate and OB-GYN who in 2013 herself was diagnosed with metastatic breast cancer. "Sexual side effects of our treatments are real impediments to our quality of life, and the quality of life of our partners."

On September 25, 2019 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 2:25 p.m. EDT on Thursday, October 3, at the Cantor Global Healthcare Conference (Press release, Puma Biotechnology, SEP 25, 2019, View Source [SID1234539774]). The conference will be held at the InterContinental New York Barclay Hotel.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Company’s website at www.pumabiotechnology.com . The presentation will be archived on the website and available for 30 days.

On September 25, 2019 Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 2:25 p.m. EDT at the InterContinental New York Barclay hotel (Press release, Heron Therapeutics, SEP 25, 2019, View Source [SID1234539773]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of this presentation will be available on the Company’s website at www.herontx.com in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.